Tags

Type your tag names separated by a space and hit enter

Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion.
Antimicrob Agents Chemother 2014; 58(3):1315-9AA

Abstract

The aim of this study was to evaluate the pharmacokinetics and penetration of moxifloxacin (MXF) in patients with various types of pleural effusion. Twelve patients with empyema/parapneumonic effusion (PPE) and 12 patients with malignant pleural effusion were enrolled in the study. A single-dose pharmacokinetic study was performed after intravenous administration of 400 mg MXF. Serial plasma (PL) and pleural fluid (PF) samples were collected during a 24-h time interval after drug administration. The MXF concentration in PL and PF was determined by high-performance liquid chromatography, and main pharmacokinetic parameters were estimated. Penetration of MXF in PF was determined by the ratio of the area under the concentration-time curve from time zero to 24 h (AUC24) in PF (AUC24PF) to the AUC24 in PL. No statistically significant differences in the pharmacokinetics in PL were observed between the two groups, despite the large interindividual variability in the volume of distribution, clearance, and elimination half-life. The maximum concentration in PF (CmaxPF) in patients with empyema/PPE was 2.23±1.31 mg/liter, and it was detected 7.50±2.39 h after the initiation of the infusion. In patients with malignant effusion, CmaxPF was 2.96±1.45 mg/liter, but it was observed significantly earlier, at 3.58±1.38 h (P<0.001). Both groups revealed similar values of AUC24PF (31.83±23.52 versus 32.81±12.66 mg·h/liter). Penetration of MXF into PF was similarly good in both patient groups (1.11±0.74 versus 1.17±0.39). Despite similar plasma pharmacokinetics, patients with empyema/parapneumonic effusion showed a significant delay in achievement of PF maximum MXF levels compared to those with malignant effusion. However, in both groups, the degree of MXF PF penetration and the on-site drug exposure, expressed by AUC24PF, did not differ according to the type of pleural effusion.

Authors+Show Affiliations

Respiratory Infections Unit, Pulmonary Department, Aristotle University of Thessaloniki, G. Papanikolaou Hospital, Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

24323477

Citation

Chatzika, Kalliopi, et al. "Moxifloxacin Pharmacokinetics and Pleural Fluid Penetration in Patients With Pleural Effusion." Antimicrobial Agents and Chemotherapy, vol. 58, no. 3, 2014, pp. 1315-9.
Chatzika K, Manika K, Kontou P, et al. Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. Antimicrob Agents Chemother. 2014;58(3):1315-9.
Chatzika, K., Manika, K., Kontou, P., Pitsiou, G., Papakosta, D., Zarogoulidis, K., & Kioumis, I. (2014). Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. Antimicrobial Agents and Chemotherapy, 58(3), pp. 1315-9. doi:10.1128/AAC.02291-13.
Chatzika K, et al. Moxifloxacin Pharmacokinetics and Pleural Fluid Penetration in Patients With Pleural Effusion. Antimicrob Agents Chemother. 2014;58(3):1315-9. PubMed PMID: 24323477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. AU - Chatzika,Kalliopi, AU - Manika,Katerina, AU - Kontou,Paschalina, AU - Pitsiou,Georgia, AU - Papakosta,Despina, AU - Zarogoulidis,Konstantinos, AU - Kioumis,Ioannis, Y1 - 2013/12/09/ PY - 2013/12/11/entrez PY - 2013/12/11/pubmed PY - 2014/10/29/medline SP - 1315 EP - 9 JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 58 IS - 3 N2 - The aim of this study was to evaluate the pharmacokinetics and penetration of moxifloxacin (MXF) in patients with various types of pleural effusion. Twelve patients with empyema/parapneumonic effusion (PPE) and 12 patients with malignant pleural effusion were enrolled in the study. A single-dose pharmacokinetic study was performed after intravenous administration of 400 mg MXF. Serial plasma (PL) and pleural fluid (PF) samples were collected during a 24-h time interval after drug administration. The MXF concentration in PL and PF was determined by high-performance liquid chromatography, and main pharmacokinetic parameters were estimated. Penetration of MXF in PF was determined by the ratio of the area under the concentration-time curve from time zero to 24 h (AUC24) in PF (AUC24PF) to the AUC24 in PL. No statistically significant differences in the pharmacokinetics in PL were observed between the two groups, despite the large interindividual variability in the volume of distribution, clearance, and elimination half-life. The maximum concentration in PF (CmaxPF) in patients with empyema/PPE was 2.23±1.31 mg/liter, and it was detected 7.50±2.39 h after the initiation of the infusion. In patients with malignant effusion, CmaxPF was 2.96±1.45 mg/liter, but it was observed significantly earlier, at 3.58±1.38 h (P<0.001). Both groups revealed similar values of AUC24PF (31.83±23.52 versus 32.81±12.66 mg·h/liter). Penetration of MXF into PF was similarly good in both patient groups (1.11±0.74 versus 1.17±0.39). Despite similar plasma pharmacokinetics, patients with empyema/parapneumonic effusion showed a significant delay in achievement of PF maximum MXF levels compared to those with malignant effusion. However, in both groups, the degree of MXF PF penetration and the on-site drug exposure, expressed by AUC24PF, did not differ according to the type of pleural effusion. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/24323477/Moxifloxacin_pharmacokinetics_and_pleural_fluid_penetration_in_patients_with_pleural_effusion_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=24323477 DB - PRIME DP - Unbound Medicine ER -